^
Association details:
Evidence:
Evidence Level:
Resistant: D – Preclinical
New
Source:
Title:

PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia

Excerpt:
Ba/F3 cells expressing the mutant AGGF1-PDGFRB were significantly more resistant to ABL inhibitors imatinib (supplemental Figure 4), dasatinib, and nilotinib (Figure 2C-D), consistent with the patient’s clinical response to these agents at relapse.
DOI:
10.1182/blood-2017-11-817510